Ser500
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser500  -  CCDC132 (human)

Site Information
RsPsVsPskQPVsTS   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 3209268

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 , 3 , 4 )
Disease tissue studied:
leukemia ( 1 ) , acute myelogenous leukemia ( 1 )
Relevant cell line - cell type - tissue:
COS (fibroblast) ( 4 ) , HeLa_Meta (cervical) ( 2 ) , HeLa_Pro (cervical) ( 2 ) , HeLa_Telo (cervical) ( 2 ) , Jurkat (T lymphocyte) ( 3 ) , KG-1 (myeloid) ( 1 )

Upstream Regulation
Treatments:
MG132_withdrawal ( 2 )

References 

1

Weber C, Schreiber TB, Daub H (2012) Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells. J Proteomics 75, 1343-56
22115753   Curated Info

2

Dulla K, et al. (2010) Quantitative site-specific phosphorylation dynamics of human protein kinases during mitotic progression. Mol Cell Proteomics 9, 1167-81
20097925   Curated Info

3

Stokes M (2008) CST Curation Set: 3886; Year: 2008; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

4

Wang Y, et al. (2007) Profiling signaling polarity in chemotactic cells. Proc Natl Acad Sci U S A 104, 8328-33
17494752   Curated Info